普萘洛尔能预防肝细胞癌吗？
Can propranalol prevent hepatocellular carcinoma?
机构信息
Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111.
出版信息
Cancer Prev Res (Phila). 2012 Aug;5(8):989-91. doi: 10.1158/1940-6207.CAPR-12-0247.
Abstract
β-Adrenergic signaling is involved in many processes that may contribute to cancer progression. In this issue of the journal (beginning on page 1007), Nkontchou and colleagues report their retrospective observational finding that the β-blocker propranolol was associated with a highly statistically significant reduction in the incidence of hepatocellular carcinoma in patients with advanced cirrhosis and related esophageal varices. This surprising finding requires confirmation, but the result is biologically plausible. Epidemiologic studies have linked β-blockers with reduced rates of metastasis of other cancers and reduced cancer mortality. Laboratory studies suggest biologic mechanisms for anticancer effects of β-blockers.
摘要
β-肾上腺素能信号参与许多可能促进癌症进展的过程。在本期杂志（从第 1007 页开始）中，Nkontchou 及其同事报告了他们的回顾性观察结果，即β受体阻滞剂普萘洛尔与晚期肝硬化和相关食管静脉曲张患者肝癌发病率的高度统计学显著降低相关。这一令人惊讶的发现需要进一步证实，但结果在生物学上是合理的。流行病学研究将β受体阻滞剂与其他癌症转移率降低和癌症死亡率降低联系起来。实验室研究表明β受体阻滞剂具有抗癌作用的生物学机制。
相似文献
1
Can propranalol prevent hepatocellular carcinoma?普萘洛尔能预防肝细胞癌吗？
Cancer Prev Res (Phila). 2012 Aug;5(8):989-91. doi: 10.1158/1940-6207.CAPR-12-0247.
2
Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis.长期普萘洛尔治疗对 HCV 相关性肝硬化患者肝细胞癌发生率的影响。
Cancer Prev Res (Phila). 2012 Aug;5(8):1007-14. doi: 10.1158/1940-6207.CAPR-11-0450. Epub 2012 Apr 23.
3
[Effects of IFN therapy on incidence of hepatocellular carcinoma in HCV positive cirrhosis].[干扰素治疗对丙型肝炎病毒阳性肝硬化患者肝细胞癌发生率的影响]
Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):600-4.
4
Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.干扰素治疗不能预防丙型肝炎病毒代偿性肝硬化患者发生肝细胞癌。
Hepatogastroenterology. 2002 Nov-Dec;49(48):1636-8.
5
The use of β-blockers is associated with a lower risk of developing hepatocellular carcinoma in patients with cirrhosis.在肝硬化患者中，使用β受体阻滞剂与肝细胞癌发生风险较低相关。
Eur J Gastroenterol Hepatol. 2016 Oct;28(10):1194-7. doi: 10.1097/MEG.0000000000000677.
6
Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.直接作用抗病毒药物的无干扰素慢性丙型肝炎治疗不会改变肝硬化患者新发肝细胞癌的短期风险。
Aliment Pharmacol Ther. 2018 Feb;47(4):516-525. doi: 10.1111/apt.14427. Epub 2017 Dec 4.
7
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.维持性聚乙二醇干扰素治疗与晚期丙型肝炎患者肝细胞癌发生的其他相关因素。
Gastroenterology. 2011 Mar;140(3):840-9; quiz e12. doi: 10.1053/j.gastro.2010.11.050. Epub 2010 Dec 1.
8
Should we continue surveillance for hepatocellular carcinoma and gastroesophageal varices in patients with cirrhosis and cured HCV infection?对于 HCV 感染后已治愈的肝硬化患者，我们是否应继续对其进行肝细胞癌和胃食管静脉曲张监测？
Eur J Intern Med. 2021 Dec;94:6-14. doi: 10.1016/j.ejim.2021.08.023. Epub 2021 Sep 23.
9
Natural History of Hepatitis C.丙型肝炎的自然史
Gastroenterol Clin North Am. 2015 Dec;44(4):717-34. doi: 10.1016/j.gtc.2015.07.003. Epub 2015 Aug 25.
10
Hepatitis C and hepatocellular carcinoma.丙型肝炎与肝细胞癌。
Ann Hepatol. 2010;9 Suppl:119-22.
引用本文的文献
1
An Integrating Immune-Related Signature to Improve Prognosis of Hepatocellular Carcinoma.整合免疫相关特征以改善肝细胞癌的预后。
Comput Math Methods Med. 2020 Nov 3;2020:8872329. doi: 10.1155/2020/8872329. eCollection 2020.
2
From rapalogs to anti-aging formula.从雷帕霉素类似物到抗衰老配方。
Oncotarget. 2017 May 30;8(22):35492-35507. doi: 10.18632/oncotarget.18033.
3
Koschei the immortal and anti-aging drugs.不朽者科谢伊与抗衰老药物。
Cell Death Dis. 2014 Dec 4;5(12):e1552. doi: 10.1038/cddis.2014.520.
4
Response.反应
J Natl Cancer Inst. 2013 May 1;105(9):668- 71. doi: 10.1093/jnci/djt063.
本文引用的文献
1
Epidemiology of viral hepatitis and hepatocellular carcinoma.病毒性肝炎与肝细胞癌的流行病学。
Gastroenterology. 2012 May;142(6):1264-1273.e1. doi: 10.1053/j.gastro.2011.12.061.
2
New directions in reducing stress effects on cancer.减轻压力对癌症影响的新方向。
Cancer Prev Res (Phila). 2012 Feb;5(2):147-9. doi: 10.1158/1940-6207.CAPR-11-0579.
3
Molecular pathways: beta-adrenergic signaling in cancer.分子通路：癌症中的β-肾上腺素能信号转导。
Clin Cancer Res. 2012 Mar 1;18(5):1201-6. doi: 10.1158/1078-0432.CCR-11-0641. Epub 2011 Dec 20.
4
β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study.β 受体阻滞剂与丹麦恶性黑色素瘤患者生存：一项基于人群的队列研究。
Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2273-9. doi: 10.1158/1055-9965.EPI-11-0249. Epub 2011 Sep 20.
5
The global epidemiology of hepatocellular carcinoma: present and future.肝细胞癌的全球流行病学：现状与未来。
Clin Liver Dis. 2011 May;15(2):223-43, vii-x. doi: 10.1016/j.cld.2011.03.006.
6
Beta blockers and breast cancer mortality: a population- based study.β受体阻滞剂与乳腺癌死亡率：一项基于人群的研究。
J Clin Oncol. 2011 Jul 1;29(19):2635-44. doi: 10.1200/JCO.2010.33.5422. Epub 2011 May 31.
7
Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.恩替卡韦与阿德福韦酯治疗失代偿期慢性乙型肝炎患者的疗效和安全性：一项随机、开放标签研究。
Hepatology. 2011 Jul;54(1):91-100. doi: 10.1002/hep.24361.
8
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.长期使用聚乙二醇干扰素治疗的晚期慢性丙型肝炎患者的超额死亡率。
Hepatology. 2011 Apr;53(4):1100-8. doi: 10.1002/hep.24169.
9
Stress influences on anoikis.压力对失巢凋亡的影响。
Cancer Prev Res (Phila). 2011 Apr;4(4):481-5. doi: 10.1158/1940-6207.CAPR-10-0358.
10
Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.聚乙二醇干扰素 alfa-2b 维持治疗不能预防肝硬化慢性丙型肝炎患者的肝细胞癌。
Gastroenterology. 2011 Jun;140(7):1990-9. doi: 10.1053/j.gastro.2011.03.010. Epub 2011 Mar 17.
Zotero 插件